Health Innovation Networks to Help Developing Countries Address Neglected Diseases

Morel, Carlos and Broun, Denis and Dangi, Ajit and Elias, Christopher and Gardner, Charles and Gupta, RK and Haycock, Jane and Heher, Tony Heher and Hotez, Peter Hotez and Juma, Calestous and Kettler, Hannah and Krattiger, Anatole and Kreutz, Fernando and Lee, Keun and al., et (2005): Health Innovation Networks to Help Developing Countries Address Neglected Diseases. Published in: Science , Vol. 309, No. July (July 2005): pp. 401-403.

Abstract

There is a great unmet need for health technologies to address diseases of the poor in developing countries. At the same time, there is a rapidly growing capability to undertake health innovation in many developing countries (Innovative Developing Countries - IDCs). The more advanced IDCs have the greatest capacity to develop, manufacture, ensure safety, and market new health products and to develop, test and introduce new health policies or strategies. They are distinguished by their rapidly growing strength in health innovation as illustrated by increasing patenting and publishing activities; increasing investments in technology by both the public and private research based sectors; rapidly growing number of health technology companies ; and proactive health systems able to analyze, evaluate and adopt new practices and technologies.

This innovation capability provides a currently underleveraged opportunity to accelerate the development of new products, policies or strategies for diseases of the poor. We are therefore calling for the formation of an Initiative for Health Product Innovation in Developing Countries. Its primary mission will be to accelerate the translation of new knowledge into health innovations relevant to the diseases of the poor and to economic growth, taking into account national priorities and sensitivities. The Initiative could promote innovation, within and among IDCs, through programs to: (i) support research on health innovation systems; (ii) promote collaboration and coordination among countries to develop, disseminate and implement good practices and policies; and (iii) implement demonstration projects.

Such an Initiative would help maximize existing and growing investments by developing countries in health research, and complement global efforts to address health disparities and achieve the Millennium Development Goals.

• Item Type: MPRA Paper
• Language: English
• Keywords: neglected disease; health product innovation; developing countries
• Subjects: I - Health, Education, and Welfare > I0 - General; O - Economic Development, Innovation, Technological Change, and Growth > O3 - Innovation ; Research and Development ; Technological Change ; Intellectual Property Rights > O35 - Social Innovation

References

See http://www.undp.org/mdg. Last referenced December 14, 2004.

See report of Global Commission on Macroeconomics and health. http://www.cmhealth.org. Last accessed December 14, 2004.

Statistical annex, World Health Report 2004, http://www.who.int/whr/2004/en, last accessed June 27, 2004.

Morel CM. “Neglected diseases: under-funded research and inadequate health interventions. Can we change this reality?” EMBO Rep. 4 Spec No: S35-S38, 2003.

Black RE, Morris SS, Bryce J. “Where and why are 10 million children dying every year?” Lancet 2003; 361: 2226-34.

Yach D, Hawkes C, Gould CL, Hofman KJ. “The global burden of chronic disease: overcoming impediments to prevention and control.” JAMA. June 2, 2004. Vol 291, No. 21. pp 2616-2622.

Kettler H, White K in consultation with Jordan S. “Valuing Industry Contributions to Public-Private Partnerships for Health Product Development.” The Initiative on Public-Private Partnerships for Health, Global Forum for Health Research, Geneva, 2003. http://www.ippph.org/index.cfm?page=/ippph/publications&thechoice=retrieve&docno=35 last accessed June 27, 2004.

See, for example: Lall S. “Indicators of the Relative Importance of IPRs in Developing Countries.” Issue Paper No. 3. Intellectual Property Rights and Sustainable Development. UNCTAD-ICTSD Project on IPRs and Sustainable Development. June 2003.

Mahoney RT. “Determinants of Innovation: A Proposed Framework.” Bellagio meeting on Accelerating Product Development and Ensuring Product Access for Diseases of Poverty: The Role of Public-Private Partnerships in Developing Countries. May 10-13, 2004 Source: http://www.globalforumhealth.org/filesupld/109004_chap_5.pdf. p. 116. 2004.

Estimate by Gardner CA, an author of this paper. The term “IDC” came into use during a meeting in Bellagio, Italy, attended by most of the current authors in May 2004. While all developing countries can innovate, some are clearly more innovative than others and may be called “advanced IDCs.”

Mashelkar RA. “Nation Building through Science & Technology -- Developing World Perspective.” 10th Zuckerman Lecture. 11 June 2003, Royal Society, London.

Mani has constructed a similar analytical framework in which he categorizes Mashelkar’s low economic strength countries as either Type 1 or Type 2. Type 1 countries have the potential to create new technologies themselves as measured by numbers of US patents issued to inventors from those countries. Type 1 countries are equivalent to what we call IDCs.

See for example: Nelson, Richard R (ed.). National Innovation Systems. Oxford University Press, Oxford, New York. 1993. p. 303. Source: http://www.uspto.gov.

Nelson RR and Pack H. The Asian Miracle and Modern Growth Theory. World Bank Working Papers Series No. 1881. October 1997.

King DA. “The scientific impact of nations: What different countries get for the research spending.” Nature 430, 311-316 (2004).

Monitoring the Financial Flows of Health Research. Global Forum for Health Research. Geneva, Global Forum for Health Research, 2001. See http://www.nature.com/nature/journal/v399/n6734/fig_tab/399299a0_F4.html. Last referenced August 27, 2004.

The 10/90 Report on Health Research 2003-2004. Global Forum for Health Research (2004). Geneva. 282 pages.

Massarani L, 2004. Brazil seeks UNESCO's aid on science funding bid. 19 May 2004 http://www.SciDev.Net.

Jayaraman KS. “Indian scientists welcome broad increase in funding.” Nature. 430, 281 (2004).

Madhavan N. “India targets $10 Bln in Biotech.” Reuters. July 11, 2004.

“Interim Report of Task Force 10 on Science, Technology and Innovation.” February 1, 2004. Millennium Project of the UN Secretary General and the UN Development Group. http://www.unmillenniumproject.org.

“Health Biotechnology Innovation in Developing Countries,” Nature Biotechnology, Volume 22 supplement, December 2004.

McKelvey M et al. (eds.). The Economic Dynamics of Modern Biotechnology, Cheltenham, UK: Edward Elgar. 2004

Outsourcing Opportunities in Indian Pharmaceutical Industry. Organisation of Pharmaceutical Producers of India. OPPI & Monitor Company Group LP, pp. 24-25. Bombay. 2003.

Bale HE. “Consumption and trade in off-patented medicines.” CMH Working Paper Series, No. WG 4: 3, WHO Commission on Macroeconomics and Health, May 2001, p. 19. http://www.cmhealth.org/docs/wg4_paper3.pdf. Last accessed December 27, 2004.

Outsourcing Opportunities in Indian Pharmaceutical Industry. Organisation of Pharmaceutical Producers of India. Bombay. 2003

Grace C. “The effect of changing intellectual property on pharmaceutical industry prospects in India and China: considerations for access to medicine,” Issues Paper, Health Systems Resource Centre, Department of International Development, United Kingdom, June 2004.

Ibid.

“Third-World Biotechnology: Southern comfort, Eastern promise.” The Economist, December 11, 2004, p. ??

“Commission on the Private Sector & Development. Unleashing entrepreneurship: making business work for the poor.” United Nations Development Programme. New York. 2004.

Kettler H and Modi R. “Building local research and development capacity for the prevention and cure of neglected diseases: the case of India.” Bull. WHO. 2001, 79(8). pp 742- 747, 2001.

Novartis has established a major research center in Singapore concerned with dengue and tuberculosis but the activities are mainly laboratory studies and not product directed. GlaxoSmithKline has a dedicated drug discovery unit in Tres Cantos, Spain which leads drug discovery initiatives in malaria and tuberculosis (http://science.gsk.com/about/disease.htm accessed June 27, 2004).

Trouiller P, Torreele E, Olliaro P, White N, Foster S, Wirth D, Pecoul B. “Drugs for neglected diseases: a failure of the market and a public health failure?” Trop. Med. and Intl. Health. 6(2), Nov. 2001. pp. 945-951.

Kettler H and Towse A. “Public private partnerships: A report for the WHO Macroeconomic Commission on Health.” www.cmhealth.org. Last accessed August 27, 2004.

Jodar L, LaForce FM, Ceccarini C, Aguado T. and Granoff D. “Meningococcal conjugate vaccine for Africa : a model for development of new vaccines for the poorest countries.” Lancet. http://image.thelancet.com/extras/02art7254web.pdf. Last accessed June 23, 2004.

Prahalad CK. “The Fortune at the Bottom of the Pyramid: Eradicating Poverty through Profits.” Wharton School Publishing. Upper Saddle River. 399 pages. 2005.

See http://www.ranbaxy.com/newsroom/pressrelease_det.asp?sno=131. Last accessed June 25, 2004.

See http://www.paho.org/english/gov/ce/ce130-10-e.pdf accessed 12/08/2004. Last accessed August 12, 2004.

Dhar B, Rao NC. Transfer of Technology for Successful Integration into the Global Economy. A Case Study of the Pharmaceutical Industry in India. UNCTAD/UNDP. New York and Geneva. 2002.

Saha R, Satyanarayana K, and Gardner CA. “Building a ‘Cottage Industry’ for Health (and Wealth): The New Framework for IP Management in India.” IP Strategy Today 10-2004, pp. 23-58.

“Health Biotechnology Innovation in Developing Countries,” Nature Biotechnology, Volume 22 supplement, December 2004.

Da Motta e Albuquerque and Cassiolato JE. “Less-developed countries and innovation in health: notes and data about the Brazilian case.” CEDEPLAR/FACE/UFMG. Belo Horizonte. 2001.

Mahoney, RT, K. Lee, MK. Yun. “IP, drug regulation, and building product innovation capability in biotechnology: the case of hepatitis B vaccine in Korea.” Manuscript. 2004.

Casper and Kettler A. “National Institutional Frameworks and the Hybridization of Entrepreneurial Business Models: The German and UK Biotechnology Sectors”, Industry and Innovation, Vol 8. 2001.

Malerba F, et al (forthcoming), Sectoral Systems of Innovation: Concepts, Issues and Analyses of Six major Sectors in Europe, Cambridge University Press.

Lee, WY. The Role of Science and Technology Policy in Korea’s Industrial Development, Technology, Learning and Innovation. Kim L and Nelson R (eds.). Cambridge University Press, Cambridge. 2000. 377 p.

Lee, K., CS Lim, and DH Park. . The Roles of the Industrial Property Rights in the Economic Development of the Republic of Korea, the World Intellectual Property Organization, 2003..

Saha R, Satyanarayana K, and Gardner CA: “Building a “Cottage Industry” for Health (and Wealth): The New Framework for IP Management in India,” IP Strategy Today, No. 10-2004, pp. 26-60.

Handbook of Best Practices for Management of Intellectual Property in Health Research and Development, published by the Centre for Management of Intellectual Property in Health Research and Development, Oxford UK, Ed. Richard T. Mahoney, pp. 129-140, November 2003

Commission on Intellectual Property Rights. Integrating Intellectual Property Rights and Development Policy. London, September 2002. Carsten Fink and Keith Maskus, eds, Intellectual Property and Development, the World Bank/ Oxford University Press, 2005.

Fraser CM. “An uncertain call to arms.” Science 304, 359 (2004).

Health Research: Essential Link to Equity in Development, Commission on Health Research for Development (1990). New York: Oxford University Press. 136 pages.

“Integrating Intellectual Property Rights and Development Policy.” Commission on Intellectual Property Rights. London, September 2002. p. 34.

See http://www.globalhealthforum.org.

Morel CM. Reaching maturity - 25 years of the TDR. Parasitol.Today 16:522-528, 2000.

See http://www.research-alliance.net/. Last accessed August 27, 2004.

Keusch G. Boston University. Personal communication. December 2004.

APEC Innovation Forum Strategic Plan, Draft. Personal communication, Stephen Matlin. Global Forum for Health Research.

See for example www.vaccinealliance.org/ site_repository/resources/herrera.ppt. Last accessed August 27, 2004.

Lucas AO. “International Collaboration in Health Research.” Commission on Macroeconomics and Health Working Paper Series, Paper No. WG2:2.

Daar AS, Thorsteinsdóttir H, Martin DK, Smith AC, Nast S, and Singer PA. “Top ten biotechnologies for improving health in developing countries.” Nat.Genet. 32 (2):229-232, 2002.